LUNG

Insider Trading Activity: Glendon E. III French, a director at $LUNG, sold 20,000 shares for approximately $157,000, representing about 2% of his holdings, while insiders have conducted 26 sales and no purchases in the last six months.

Institutional and Analyst Insights: In the latest quarter, 60 institutional investors increased their positions in $LUNG, while 65 decreased theirs; analysts have issued three buy ratings with no sell ratings on the stock recently.

Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.

Analyst Ratings Initiations: Several Wall Street analysts have initiated coverage on various companies, including SailPoint, Karman Holdings, Pulmonx Corporation, and Aardvark Therapeutics, all receiving Buy ratings with specific price targets set above their current share prices.

Current Stock Performance: As of the latest closing prices, SailPoint shares were at $22.05, Karman at $28.78, Pulmonx at $7.48, and Aardvark at $10.13, indicating potential growth based on analysts' optimistic outlooks.

Analyst Rating and Price Target: Lake Street analyst Frank Takkinen maintains a Buy rating on Pulmonx (LUNG) with a price target of $12.00, while the stock closed at $6.83, indicating potential upside.

Insider Activity and Market Sentiment: Despite a Moderate Buy consensus rating for Pulmonx, recent insider activity shows negative sentiment, with an increase in insiders selling shares, including a notable sale by David Aaron Lehman.

Insider Trading Activity: Glendon E. III French, a director at $LUNG, sold 2,221 shares for approximately $14,436 on January 17, 2025, reducing their holdings to 1,067,427 shares; in the past six months, insiders have predominantly sold shares, with 21 sales and only 1 purchase.

Institutional Investor Movements: In the latest quarter, 62 institutional investors increased their positions in $LUNG stock while 52 reduced theirs, indicating mixed sentiment among larger shareholders.

Fastest News Alerts: Benzinga Pro offers real-time intelligence and alerts to help traders stay informed and make winning trades in the stock market.

Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and accurate market intelligence.

Business Risks: Pulmonx Corporation faces significant risks that could affect its financial stability, including a history of net losses, reliance on a single product (Zephyr Endobronchial Valve), and challenges in market adoption due to resistance from hospitals and physicians.

Market Consensus: Despite these risks, Wall Street maintains a Strong Buy consensus rating for LUNG stock, supported by 4 Buys and 1 Hold.

Earnings Performance: Pulmonx Corporation reported a quarterly loss of $0.36 per share, better than the expected loss of $0.43, marking an earnings surprise of 16.28%. The company also posted revenues of $20.39 million, slightly missing estimates but showing growth from $17.67 million a year ago.

Market Outlook: Despite underperforming the market with a 46.9% decline in shares this year, Pulmonx holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and management's commentary during the earnings call.

Analyst Rating: Larry Biegelsen from Wells Fargo has maintained a Hold rating on Pulmonx (LUNG), with the stock currently valued at $7.31, while the analyst consensus suggests a Moderate Buy with an average price target of $12.67.

Company Performance: Pulmonx reported a quarterly revenue of $20.78 million and a GAAP net loss of $15.33 million for the quarter ending June 30, showing improvement compared to the previous year's revenue and loss figures.

Investor Meetings Announcement: Pulmonx Corporation will participate in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on September 14, 2024.

Company Overview: Pulmonx is a leader in minimally invasive treatments for severe lung diseases like COPD, with its Zephyr® Endobronchial Valve recognized as a standard treatment option and available in over 25 countries.

Health Care Stocks Performance: Health care stocks saw an increase on Friday, with the NYSE Health Care Index rising by 0.4% and the iShares Biotechnology ETF climbing 1.2%. Notable corporate movements included Surgery Partners' shares jumping nearly 17% due to acquisition interest from TPG and UnitedHealth.

Drug Pricing and Approvals: Johnson & Johnson announced changes in drug pricing for hospitals, while Moderna received EU approval for its respiratory syncytial virus vaccine for older adults, leading to respective share price increases of 1.1% and 1.5%.

Health Care Stock Performance: Health care stocks saw modest gains, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund increasing by 0.3%, while the iShares Biotechnology ETF rose by 1.1%.

Corporate News Highlights: Moderna received EU approval for its RSV vaccine for older adults, leading to a 1.3% rise in its shares; Pulmonx shares surged 9.2% following stock purchases by its CEO, and Align Technology's shares increased by 2.3% after announcing a promotional program for Invisalign at Costco.

Earnings Performance: Pulmonx Corporation reported a quarterly loss of $0.39 per share, slightly better than the expected loss of $0.41, and achieved revenues of $20.78 million, surpassing estimates by 2.72%. The company has consistently exceeded consensus EPS and revenue estimates over the past four quarters.

Market Outlook: Despite underperforming the market with a 44.6% decline in shares this year, Pulmonx holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market. Future stock movements will depend on earnings estimate revisions and industry outlook, as well as upcoming results from peers like Axonics Modulation Technologies.

Pulmonx Corporation Stock Analysis:

• Shares of Pulmonx Corporation (LUNG) have risen by 17.1% in the past four weeks, closing at $8.78.
• Analysts suggest a potential upside of 80.3% with a mean price target of $15.83 for LUNG stock.
• A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's potential.
• Analysts' price targets are often influenced by business incentives and may not always accurately predict stock movements.
• Despite the importance of price targets, investors should approach them with caution and conduct further research.

Analysts' Price Targets and Stock Movement:

• Price targets set by analysts can mislead investors more than guide them, according to empirical research.
• Analysts may set optimistic price targets to generate interest in certain stocks due to business relationships.
• Tight clustering of price targets suggests agreement among analysts but does not guarantee hitting the target.
• Investors should not solely rely on price targets for investment decisions to avoid potential disappointment in returns.

Upside Potential in LUNG Stock:

• Analysts are optimistic about Pulmonx Corporation's earnings prospects, leading to higher EPS estimates.
• Strong agreement among analysts in revising estimates upward can indicate potential stock upside.
• The Zacks Consensus Estimate for LUNG has increased by 8.7% over the last 30 days.
• LUNG holds a Zacks Rank #2 (Buy), indicating potential upside based on earnings-related factors.